Calidi Biotherapeutics (CLDI) News Today $1.60 +0.03 (+1.91%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Calidi Biotherapeutics Updates Presentation DisclosureAugust 29, 2025 | tipranks.comCalidi Biotherapeutics (NYSE:CLDI) CEO Eric Poma Buys 25,000 SharesAugust 26, 2025 | insidertrades.comCalidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment OptionAugust 22, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment OptionAugust 21, 2025 | globenewswire.comCalidi prices 1.47M units at $2.00 in underwritten public offeringAugust 20, 2025 | msn.comCalidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public OfferingAugust 20, 2025 | globenewswire.comCalidi Biotherapeutics Secures FDA Fast Track DesignationAugust 17, 2025 | theglobeandmail.comCalidi Biotherapeutics Announces Executive Departure AgreementAugust 14, 2025 | msn.comCalidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational HighlightsAugust 8, 2025 | globenewswire.comCalidi Biotherapeutics Inc trading resumesAugust 5, 2025 | msn.comCalidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025July 25, 2025 | globenewswire.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24July 22, 2025 | finance.yahoo.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24July 22, 2025 | globenewswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million ...July 11, 2025 | morningstar.comMCalidi Biotherapeutics secures $4.6 million through warrant exerciseJuly 11, 2025 | investing.comCalidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer TreatmentJuly 10, 2025 | globenewswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross ProceedsJuly 9, 2025 | globenewswire.comCalidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer TreatmentJuly 8, 2025 | globenewswire.comCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Shareholder Letter from CEOJune 27, 2025 | finanznachrichten.deCalidi Biotherapeutics Announces Shareholder Letter from CEOJune 27, 2025 | globenewswire.comCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 16, 2025 | finanznachrichten.deCalidi Biotherapeutics Strengthens Leadership Team and Advances Antitumor Virotherapy Platform with New CEO and Chief Medical Officer AppointmentsMay 16, 2025 | nasdaq.comCalidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 15, 2025 | tmcnet.comCalidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual MeetingApril 28, 2025 | finance.yahoo.comCalidi reports inducement grant unders NYSE American guideApril 26, 2025 | markets.businessinsider.comCalidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711April 25, 2025 | globenewswire.comCalidi appoints Eric Poma as CEO, directorApril 24, 2025 | markets.businessinsider.comCalidi announces FDA clearance of IND application for CLD-201April 18, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid TumorsApril 17, 2025 | markets.businessinsider.comCalidi appoints Guy Travis Clifton as CMO, Consultant, AdvisorApril 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and AdvisorApril 10, 2025 | finance.yahoo.comCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational HighlightsMarch 31, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 31, 2025 | globenewswire.comCalidi Biotherapeutics Provides Update On Phase 1 Trial Of CLD-101 For Recurrent GliomaMarch 28, 2025 | nasdaq.comCalidi prices 3.33M shares at 65c in registered direct offeringMarch 28, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementMarch 28, 2025 | globenewswire.comCalidi, City of Hope provide update on Phase 1 trial with CLD-101March 27, 2025 | markets.businessinsider.comIBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | finance.yahoo.comCalidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy PlatformMarch 11, 2025 | theglobeandmail.comCalidi announces ability to deliver transient gene therapy to tumorsMarch 10, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic PlatformMarch 10, 2025 | globenewswire.comCalidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVFebruary 28, 2025 | finanznachrichten.deCalidi commences recruitment for multiple dose CLD-101 trialFebruary 24, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University HospitalFebruary 24, 2025 | globenewswire.comCalidi Biotherapeutics expands stock offering capacityFebruary 5, 2025 | msn.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5January 30, 2025 | markets.businessinsider.comCLDI Stock Plummets to 52-Week Low at $0.6 Amid Market TurbulenceJanuary 30, 2025 | msn.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5January 29, 2025 | globenewswire.comCalidi announces termination of standby equity purchase agreementJanuary 29, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase AgreementJanuary 28, 2025 | globenewswire.com Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDI Media Mentions By Week CLDI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDI News Sentiment▼0.000.72▲Average Medical News Sentiment CLDI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDI Articles This Week▼01▲CLDI Articles Average Week Get the Latest News and Ratings for CLDI and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Calidi Biotherapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Abpro News Today Ainos News Today 180 Life Sciences News Today Lexaria Bioscience News Today Mannatech News Today Edesa Biotech News Today LakeShore Biopharma News Today Lipocine News Today Cyclacel Pharmaceuticals News Today Moleculin Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CLDI) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
